Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8446 to 8460 of 8990 results

  1. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued Reference number: GID-TA10583

    Technology appraisal guidance
    Discontinued

  3. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    In development Reference number: GID-TA11655 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Suspected cancer (QS124)

    April 2026: We have withdrawn this quality standard following the launch of the updated NICE guideline on suspected cancer: recognition and referral. An updated NICE quality standard for suspected cancer is being developed.  For any queries, please contact qualitystandards@nice.org.uk.

    Withdrawn quality standard

  5. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    This guidance has been updated and replaced by NICE HealthTech guidance 733.

    Withdrawn guidance

  6. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    In development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473]

    In development Reference number: GID-TA11582 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Inebilizumab for treating immunoglobulin G4-related disease [ID6600]

    In development Reference number: GID-TA11665 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    Discontinued Reference number: GID-TA11009

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

    Discontinued Reference number: GID-TA10668

    Technology appraisal guidance
    Discontinued

  12. Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]

    In development Reference number: GID-TA11310 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

    Technology appraisal guidance
    Discontinued

  14. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued Reference number: GID-TA10416

    Technology appraisal guidance
    Discontinued

  15. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

    Technology appraisal guidance
    Discontinued